1. Key Insights
2. Executive Summary of Peripheral T-cell Lymphoma (PTCL)
3. Peripheral T-cell Lymphoma (PTCL) Market Overview at a Glance
3.1. Market Share (%) Distribution of Peripheral T-cell Lymphoma (PTCL) in 2017
3.2. Market Share (%) Distribution of Peripheral T-cell Lymphoma (PTCL) in 2030
4. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)
4.1. Introduction
4.2. Classification of PTCL
4.2.1. WHO Classification System
4.3. Subtypes of PTCL
4.3.1. Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)
4.3.2. Anaplastic Large Cell Lymphoma (ALCL)
4.3.3. Angioimmunoblastic T-Cell Lymphoma (AITL)
4.4. Signs and Symptoms
4.5. Cause of PTCL
4.6. Pathophysiology
4.7. Other conditions that can mimic PTCL
4.8. Staging
4.9. Diagnosis
4.9.1. Blood tests
4.9.2. Diagnostic Scans
5. Case Reports
5.1. A case of peripheral T-cell lymphoma, not otherwise specified in an HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology
5.2. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion
5.3. Peripheral T-cell Lymphoma with eosinophilia presenting as monoarthritis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. Epidemiology Methodology
6.4. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM
7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States
7.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States
7.4. Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the United States
8. EU5 Epidemiology
8.1. Assumptions and Rationale
8.2. Germany Epidemiology
8.2.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany
8.2.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany
8.2.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany
8.3. France Epidemiology
8.3.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France
8.3.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France
8.3.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France
8.4. Italy Epidemiology
8.4.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy
8.4.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy
8.4.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy
8.5. Spain Epidemiology
8.5.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain
8.5.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain
8.5.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain
8.6. United Kingdom Epidemiology
8.6.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK
8.6.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK
8.6.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK
9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan
9.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan
9.4. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan
10. Treatment
10.1. Treatment Goals
10.1.1. Treatment for Newly Diagnosed Patients
10.1.2. Treatment for Patients with Relapsed or Refractory PTCL
10.2. Treatment Options
10.2.1. Chemotherapy
10.2.2. Radiotherapy
10.2.3. Steroids
10.2.4. Bone marrow transplantation or Stem cell transplantation
10.2.5. Medications
10.2.6. Therapeutic Approaches
10.3. Prospective Treatments
10.3.1. PI3 kinase pathway
10.3.2. Epigenetic therapies
10.3.3. Antibody-based therapies
10.3.4. Immune checkpoint inhibitors
10.4. Personalized Treatment and Biomarkers
10.5. Conclusion
10.6. Treatment Guidelines
10.6.1. United States
10.6.2. Europe
11. Unmet needs
12. Marketed Drugs
12.1. Beleodaq (Belinostat): Onxeo S.A.
12.1.1. Drug Description
12.1.2. Mechanism of Action
12.1.3. Other development Activities
12.1.4. Clinical Trial Information
12.1.5. Advantages & Disadvantages
12.1.6. Safety and Efficacy of Beleodaq
12.1.7. Product Profile
12.2. Istodax (Romidepsin): Celgene Corporation
12.2.1. Drug Description
12.2.2. Mechanism of Action
12.2.3. Other Developmental Activities
12.2.4. Clinical Trial Information
12.2.5. Advantages and Disadvantages
12.2.6. Safety and Efficacy of Istodax
12.2.7. Product Profile
12.3. Folotyn (Pralatrexate): Spectrum Pharmaceuticals
12.3.1. Drug Description
12.3.2. Mechanism of Action
12.3.3. Other Developmental Activities
12.3.4. Clinical Trial Information
12.3.5. Advantages & Disadvantages
12.3.6. Safety and Efficacy of Folotyn
12.3.7. Product Profile
12.4. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
12.4.1. Drug Description
12.4.2. Mechanism of Action
12.4.3. Other Developmental Activities
12.4.4. Clinical Trial Information
12.4.5. Advantages & Disadvantages
12.4.6. Safety and Efficacy of Poteligeo
12.4.7. Product Profile
12.5. Adcetris (Brentuximab vedotin): Seattle Genetics
12.5.1. Drug Description
12.5.2. Mechanism of Action
12.5.3. Other Developmental Activities
12.5.4. Clinical Trial Information
12.5.5. Advantages & Disadvantages
12.5.6. Safety and Efficacy of Adcetris
12.5.7. Product Profile
12.6. Mundesine (Forodesine Hydrochloride): Mundipharma K. K.
12.6.1. Drug Description
12.6.2. Mechanism of Action
12.6.3. Other Developmental Activities
12.6.4. Clinical Trial Information
12.6.5. Safety and Efficacy
12.6.6. Product Profile
12.7. Rituxan (MabThera): Genentech
12.7.1. Drug Description
12.7.2. Mechanism of Action
12.7.3. Clinical Trial Information
12.7.4. Advantages and Disadvantages
12.7.5. Safety and Efficacy of Rituxan
12.7.6. Product Profile
12.8. Arranon (nelarabine): GlaxoSmithKline
12.8.1. Product Description
12.8.2. Regulatory Milestones
12.8.3. Safety and Efficacy
12.8.4. Product Profile
13. Emerging Drugs
13.1. Key Cross Competition
13.2. Denileukin diftitox: Eisai
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. Fenretinide (4-HPR): CerRx
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Safety and Efficacy
13.4.5. Product Profile
13.5. Tipifarnib: Kura Oncology
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. HBI-8000: HUYA Bioscience International/Quintiles, Inc.
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Safety and Efficacy
13.6.5. Product Profile
13.7. COPIKTRA (Duvelisib): Verastem
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Safety and Efficacy
13.7.5. Product Profile
13.8. Genolimzumab (GB226): Genor Biopharma
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Safety and Efficacy
13.8.5. Product Profile
13.9. Azacitidine (CC-486): Celgene Corporation
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile
13.10. Tislelizumab: BeiGene
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Safety and Efficacy
13.10.5. Product Profile
13.11. Lacutamab/IPH4102: Innate Pharma
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Product Profile
13.12. AFM13: Affimed GmbH
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Product Profile
13.13. Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
13.13.1. Product Description
13.13.2. Other Developmental Activity
13.13.3. Clinical Development
13.13.4. Product Profile
13.14. Bavencio (avelumab): Pfizer
13.14.1. Product Description
13.14.2. Clinical Development
13.14.3. Product Profile
13.15. Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
13.15.1. Product Description
13.15.2. Clinical Development
13.15.3. Safety and Efficacy
13.15.4. Product Profile
13.16. STI-3031/IMC-001: Sorrento Therapeutics
13.16.1. Product Description
13.16.2. Other Developmental Activities
13.16.3. Clinical Development
13.16.4. Product Profile
13.17. ALRN 6924: Aileron Therapeutics
13.17.1. Product Description
13.17.2. Other Developmental Activities
13.17.3. Clinical Development
13.17.4. Safety and Efficacy
13.17.5. Product Profile
13.18. Masitinib: AB Science
13.18.1. Product Description
13.18.2. Clinical Development
13.18.3. Product Profile
13.19. Ruxolitinib: Incyte Corporation/Novartis
13.19.1. Product Description
13.19.2. Other Developmental Activities
13.19.3. Clinical Development
13.19.4. Safety and Efficacy
13.19.5. Product Profile
13.20. Aplidin (plitidepsin): PharmaMar
13.20.1. Product Description
13.20.2. Other Developmental Activities
13.20.3. Clinical Development
13.20.4. Safety and Efficacy
13.20.5. Product Profile
13.21. ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals
13.21.1. Product Description
13.21.2. Other Developmental Activities
13.21.3. Clinical Development
13.21.4. Safety and Efficacy
13.21.5. Product Profile
14. Peripheral T-cell Lymphoma (PTCL): Seven Major Market Analysis
14.1. Key Findings
14.2. Market Methodology
14.3. Market Size of Peripheral T-cell Lymphoma (PTCL) in the 7MM
14.4. Market Size of Peripheral T-cell Lymphoma (PTCL) by Therapies in the 7MM
14.4.1. Market Size of Peripheral T-cell Lymphoma (PTCL) by First-line Therapies in the 7MM
14.4.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by Second-line Therapies in the 7MM
15. CD30 expression in peripheral T-cell lymphomas
16. Expected Launch Year of Emerging Therapies
17. Attribute Analysis Phase III
18. Attribute Analysis Phase II
19. United States Market Outlook
19.1. United States Market Size
19.1.1. Total market size of Peripheral T-cell Lymphoma (PTCL) in the United States
19.1.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by Therapies in the United States
20. EU-5 Market Outlook
20.1. Germany Market Size
20.1.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Germany
20.1.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Germany
20.2. France Market Size
20.2.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in France
20.2.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in France
20.3. Italy Market Size
20.3.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Italy
20.3.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Italy
20.4. Spain Market Size
20.4.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Spain
20.4.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Spain
20.5. United Kingdom Market Size
20.5.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in the United Kingdom
20.5.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in the UK
21. Japan Market Outlook
21.1. Japan Market Size
21.1.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Japan
21.1.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Japan
22. Market Drivers
23. Market Barriers
24. SWOT Analysis
25. Reimbursement and Market Access
26. Recognized Establishments
27. Appendix
27.1. Bibliography
27.2. Report Methodology
28. DelveInsight Capabilities
29. Disclaimer
30. About DelveInsight
Table 1 Summary of Peripheral T-cell Lymphoma (PTCL), Market, Epidemiology and Key Events (2017–2030)Table 2 Old and New WHO classifications of PTCLs
Table 3 Subtypes of PTCL
Table 4 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM (2017–2030)
Table 5 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)
Table 6 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)
Table 7 Subtype-specific Incident Cases of PTCL in the US (2017–2030)
Table 8 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)
Table 9 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)
Table 10 Subtype-specific Incident Cases of PTCL in Germany (2017–2030)
Table 11 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)
Table 12 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)
Table 13 Subtype-specific Incident Cases of PTCL in France (2017–2030)
Table 14 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)
Table 15 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)
Table 16 Subtype-specific Incident Cases of PTCL in Italy (2017–2030)
Table 17 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)
Table 18 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)
Table 19 Subtype-specific Incident Cases of PTCL in Spain (2017–2030)
Table 20 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)
Table 21 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)
Table 22 Subtype-specific Incident Cases of PTCL in the United Kingdom (2017–2030)
Table 23 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)
Table 24 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)
Table 25 Subtype-specific Incident Cases of PTCL in Japan (2017–2030)
Table 26 Treatment for Patients with Relapsed or Refractory PTCL
Table 27 Beleodaq, Clinical Trial Description, 2020
Table 28 Istodax (Romidepsin), Clinical Trial Description, 2020
Table 29 Folotyn (Pralatrexate): Clinical Trial Description, 2020
Table 30 Poteligeo (Mogamulizumab): Clinical Trial Description, 2020
Table 31 Adcetris (Brentuximab vedotin): Clinical Trial Description, 2020
Table 32 Mundesine (Forodesine Hydrochloride): Clinical Trial Description, 2020
Table 33 Rituxan (MabThera): Clinical Trial Description, 2020
Table 34 Comparison of emerging drugs under development
Table 35 Denileukin diftitox (DD), Clinical Trial Description, 2020
Table 36 SP-02 (darinaparsin), Clinical Trial Description, 2020
Table 37 Fenretinide, Clinical Trial Description, 2020
Table 38 Tipifarnib, Clinical Trial Description, 2020
Table 39 HBI-8000, Clinical Trial Description, 2020
Table 40 COPIKTRA (Duvelisib), Clinical Trial Description, 2020
Table 41 Genolimzumab (GB226), Clinical Trial Description, 2020
Table 42 Azacitidine (CC-486), Clinical Trial Description, 2020
Table 43 Tislelizumab (BGB-A317), Clinical Trial Description, 2020
Table 44 Lacutamab (IPH4102), Clinical Trial Description, 2020
Table 45 AFM13, Clinical Trial Description, 2020
Table 46 Opdivo + Cabiralizumab, Clinical Trial Description, 2020
Table 47 Bavencio, Clinical Trial Description, 2020
Table 48 Keytruda, Clinical Trial Description, 2020
Table 49 STI-3031, Clinical Trial Description, 2020
Table 50 ALRN-6924, Clinical Trial Description, 2020
Table 51 Masitinib, Clinical Trial Description, 2020
Table 52 Ruxolitinib, Clinical Trial Description, 2020
Table 53 Aplidin, Clinical Trial Description, 2020
Table 54 ASTX660, Clinical Trial Description, 2020
Table 55 Market Size of Peripheral T-cell Lymphoma (PTCL) in the 7MM in USD Million (2017–2030)
Table 56 Market Size of Peripheral T-cell Lymphoma (PTCL) by first-line therapies in the 7MM, in USD Million (2017–2030)
Table 57 Market Size of Peripheral T-cell Lymphoma (PTCL) by second-line therapies in the 7MM, in USD Million (2017–2030)
Table 58 Expected Launch Year of Potential Emerging Therapies
Table 59 The US Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 60 Market Size of PTCL by First-line therapies in the US, in USD Million (2017–2030)
Table 61 Market Size of PTCL by Second-line therapies in the US, in USD Million (2017–2030)
Table 62 Germany Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 63 Market Size of PTCL by First-line therapies in Germany, in USD Million (2017–2030)
Table 64 Market Size of PTCL by Second-line therapies in Germany, in USD Million (2017–2030)
Table 65 France Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 66 Market Size of PTCL by First-line therapies in France, in USD Million (2017–2030)
Table 67 Market Size of PTCL by Second-line therapies in France, in USD Million (2017–2030)
Table 68 Italy Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 69 Market Size of PTCL by First-line therapies in Italy, in USD Million (2017–2030)
Table 70 Market Size of PTCL by Second-line therapies in Italy, in USD Million (2017–2030)
Table 71 Spain Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 72 Market Size of PTCL by First-line therapies in Spain, in USD Million (2017–2030)
Table 73 Market Size of PTCL by Second-line therapies in Spain, in USD Million (2017–2030)
Table 74 The UK Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 75 Market Size of PTCL by First-line therapies in the UK, in USD Million (2017–2030)
Table 76 Market Size of PTCL by Second-line therapies in the UK, in USD Million (2017–2030)
Table 77 Japan Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017–2030)
Table 78 Market Size of PTCL by First-line therapies in Japan, in USD Million (2017–2030)
Table 79 Market Size of PTCL by Second-line therapies in Japan, in USD Million (2017–2030)
List of Figures
Figure 1 Classification of PTCL
Figure 2 T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
Figure 3 KOL Views
Figure 4 KOL Views
Figure 5 KOL Views
Figure 6 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM (2017–2030)
Figure 7 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)
Figure 8 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)
Figure 9 Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the US (2017–2030)
Figure 10 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)
Figure 11 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)
Figure 12 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)
Figure 13 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)
Figure 14 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)
Figure 15 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)
Figure 16 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)
Figure 17 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)
Figure 18 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)
Figure 19 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)
Figure 20 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)
Figure 21 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)
Figure 22 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)
Figure 23 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)
Figure 24 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)
Figure 25 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)
Figure 26 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)
Figure 27 Subtype-specific Incident Cases of PTCL in Japan (2017–2030)
Figure 28 First Line of therapy for PTCL-NOS
Figure 29 Second Line of therapy for PTCL-NOS with Stem cell transplant
Figure 30 First Line of therapy for ALCL, ALK+
Figure 31 Second Line of therapy for ALCL- ALK+ with Stem cell transplant
Figure 32 First Line of therapy for ALCL-ALK
Figure 33 Second Line of therapy for ALCL-ALK− with Stem cell transplant
Figure 34 First Line of therapy for AICL
Figure 35 Second Line of therapy for AICL with Stem cell transplant
Figure 36 First Line of therapy for EATCL
Figure 37 Second Line of therapy for enetropathy associated T cell lymphoma with stem cell transplantation
Figure 38 Integrated Management Algorithm for PTCL
Figure 39 Treatment for relapsed/ refractory Nodal and Extranodal Peripheral T-cell Lymphoma
Figure 40 Unmet Needs of PTCL
Figure 41 Market Size of Peripheral T-cell Lymphoma (PTCL) in the 7MM in USD Million (2017–2030)
Figure 42 Market Size of Peripheral T-cell Lymphoma (PTCL) by first-line therapies in the 7MM, in USD Million (2017–2030)
Figure 43 Market Size of Peripheral T-cell Lymphoma (PTCL) by second-line therapies in the 7MM, in USD Million (2017–2030)
Figure 44 Market Size of Peripheral T-cell Lymphoma (PTCL) in the US, USD Millions (2017–2030)
Figure 45 Market Size of PTCL by First-line therapies in the US, in USD Million (2017–2030)
Figure 46 Market Size of PTCL by Second-line therapies in the US, in USD Million (2017–2030)
Figure 47 Market Size of Peripheral T-cell Lymphoma (PTCL) in Germany, USD Millions (2017–2030)
Figure 48 Market Size of PTCL by First-line therapies in Germany, in USD Million (2017–2030)
Figure 49 Market Size of PTCL by Second-line therapies in Germany, in USD Million (2017–2030)
Figure 50 Market Size of Peripheral T-cell Lymphoma (PTCL) in France, USD Millions (2017–2030)
Figure 51 Market Size of PTCL by First-line therapies in France, in USD Million (2017–2030)
Figure 52 Market Size of PTCL by Second-line therapies in France, in USD Million (2017–2030)
Figure 53 Market Size of Peripheral T-cell Lymphoma (PTCL) in Italy, USD Millions (2017–2030)
Figure 54 Market Size of PTCL by First-line therapies in Italy, in USD Million (2017–2030)
Figure 55 Market Size of PTCL by Second-line therapies in Italy, in USD Million (2017–2030)
Figure 56 Market Size of Peripheral T-cell Lymphoma (PTCL) in Spain, USD Millions (2017–2030)
Figure 57 Market Size of PTCL by First-line therapies in Spain, in USD Million (2017–2030)
Figure 58 Market Size of PTCL by Second-line therapies in Spain, in USD Million (2017–2030)
Figure 59 Market Size of Peripheral T-cell Lymphoma (PTCL) in the UK, USD Millions (2017–2030)
Figure 60 Market Size of PTCL by First-line therapies in the UK, in USD Million (2017–2030)
Figure 61 Market Size of PTCL by Second-line therapies in the UK, in USD Million (2017–2030)
Figure 62 Market Size of Peripheral T-cell Lymphoma (PTCL) in Japan, USD Millions (2017–2030)
Figure 63 Market Size of PTCL by First-line therapies in Japan, in USD Million (2017–2030)
Figure 64 Market Size of PTCL by Second-line therapies in Japan, in USD Million (2017–2030)
Figure 65 Market Drivers
Figure 66 Market Barriers
Figure 67 SWOT Analysis of Peripheral T-Cell Lymphoma (PTCL)
【免責事項】
https://www.marketreport.jp/reports-disclaimer